Clinical Investigation of Safety and Effectiveness of Emerald IPLdevice

1. Be willing to provide informed consent
2. Are healthy female subjects, in age of 18-65 years

3. Have natural body hair color that is dark blonde, brown or black in the designated treatment areas

   3.1. Subjects of ST I-IV - Face group:

   3.1.1 Have Fitzpatrick Skin Type I, II, III, or IV

   3.1.2 Measure melanin value ≤ 375 in the qualifying treatment areas bilateral on upper lip (face)

   3.1.3. Have a minimum of 10 hairs in the 1x2cm2 qualifying treatment areas bilateral on upper lip (face), by visual inspection

   3.2. Subjects of ST V - All body area group:

   3.2.1. Have Fitzpatrick Skin Type V

   3.2.2. Measure melanin value ≤ 553 in the qualifying treatment areas bilateral on upper lip (face), axilla, bikini line, and leg

   3.2.3. Have a minimum of 10 hairs in the 1x2cm2 qualifying treatment areas bilateral on upper lip (face), by visual inspection

   3.2.4.Have a minimum of 24 hairs in each of the 2x4cm2 qualifying treatment areas bilateral on axilla, bikini line, and leg, by visual inspection

4. Be either post-menopausal or surgically sterilized, or using a medically acceptable form of birth control (e.g., oral contraceptives, IUD, contraceptive implant, barrier methods with spermicide or abstinence, etc.).
5. Be willing to participate in all study visits
6. Be willing to refrain from deliberate exposure to strong sun, products or procedures that would cause the skin to become darker in the designated treatment areas during the treatment phase
7. Be willing to refrain from the use of hair growth inhibitors/accelerators during the course of the study
8. Be willing to refrain from waxing, depilating or epilating of the axilla, bikini line, leg, and face
9. Be willing to refrain from using aspirin or NSAIDs (e.g. acetaminophen, ibuprofen, etc.) within 5 days prior to and 5 days after treatment(s) -

Exclusion Criteria:

1. Have natural body hair color that is white, light blond, or red in the designated treatment areas

   1.1. Subjects of ST I to IV - Face group:

   1.1.1. Have Fitzpatrick Skin Type V or VI

   1.1.2. Measure melanin value higher than 375 in the qualifying treatment areas bilateral on upper lip

   1.1.3. Have fewer than 2 qualifying treatment areas on bilateral on upper lip (face)

   1.2. Subjects of ST V - All body area group:

   1.2.1. Have Fitzpatrick Skin Type I, II, III, IV, or VI

   1.2.2. Measure melanin value higher than 553 in any of the qualifying treatment areas bilateral on the body

   1.2.3. Have fewer than 8 qualifying treatment areas bilateral: 2 in face, 2 in axilla, 2 on bikini line, and 2 on legs

2. Have a malignant or pre-malignant pigment in the area to be treated
3. Have scarring or infection of the area to be treated
4. Have a known history of photosensitivity or use of medication known to induce photosensitivity
5. Are currently pregnant or lactating or planning be become pregnant in the period of the study, per subject report
6. Are currently on a daily dose of aspirin or NSAIDs (e.g. acetaminophen, ibuprofen, etc.) or have taken aspirin and/or NSAIDs within 5 days prior to treatment that would reduce or increase the sensation of pain
7. Are not willing to abstain from the use of products or light exposure that would induce tanning in the treatment areas during the IPL treatment period (first 10 months)
8. Have a history of immunosuppressive disease (including HIV infection or AIDS)
9. Are on a anticoagulative medication or thromboembolic condition
10. Have taken any form of isotretinoin (such as Accutane or Roaccutane etc.) in the last six months
11. Have an active implantable device such as a pacemaker, neurostimulator or internal defibrillator
12. Have used waxing or other methods of root hair removal, or photo-epilation in the areas to be treated within 6 months prior to treatment
13. Have been exposed to strong sunlight or an artificial tanning machine in the area to be treated within 4 weeks of enrolment
14. Have a tattoo(s), warts, moles, benign skin lesions, dark pigmented areas, permanent make-up etc. in the areas to be treated.
15. Have eczema, psoriasis, lesions, open wounds or any skin affliction in the areas to be treated
16. Have a history of keloid scar formation
17. Have a history of herpes outbreaks in the areas to be treated
18. Have a history of photosensitive epilepsy
19. Have a condition related to hormonal changes like polycystic ovarian syndrome (PCOS) or taking drugs leading to hormonal changes resulting in excessive hair growth like hirsutism or idiopathic hirsutism
20. Have diabetes, or metabolic disease that affects hair growth
21. Taking immunosuppressive medication(s)
22. Have a disease related to photosensitivity, such as polymorphic light eruption (PMLE), solar urticaria, porphyria etc.
23. Have a history of skin cancer, including past basal cell carcinoma and/or squamous cell carcinoma in the areas to be treated
24. Have a history of any radiation therapy in any of the areas to be treated
25. Have history of radiation therapy in non-treatment areas within 5 years
26. Have a history of chemotherapy
27. Have used hair growth inhibitors and/or accelerators within 6 months preceding enrolment
28. Have had laser or electrolysis treatment for the removal of hair in the areas to be treated within the last year
29. Have natural body hair colors of white, grey, light to mid-blond, or red in the areas to be treated
30. Have bleaching of their body hair in the areas to be treated 6 months prior to study enrolment
31. Have shaved the areas to be treated within 7 days prior to study enrolment
32. Participating in other clinical studies prior to, or concurrently with this study, that could be deemed to interfere with full and complete participation in this study - as determined by the site investigator.